Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 4/20 | 0.52 |
| ▸ | HTR2B | P41595 | 3/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13849354 | 0.84 | SYK (0.64) | SYKPOLBHTR2CHTR2BPDPK1 | |
| SCHEMBL12845584 | 0.84 | SYK (0.64) | SYKPOLBHTR2CHTR2BPDPK1 | |
| SCHEMBL16536992 | 0.83 | CHEK1 (0.55) | SYKPOLBHTR2CHTR2BPDPK1 | |
| SCHEMBL2085669 | 0.82 | SYK (0.58) | SYKPOLBHTR2CHTR2BKIT | |
| SCHEMBL212928 | 0.82 | HTR2C (0.59) | SYKPOLBHTR2CHTR2BKIT | |
| SCHEMBL29788588 | 0.81 | ALDH1A1 (0.58) | SYKHTR2BTSHRCYP2D6HTR2A | |
| SCHEMBL375708 | 0.81 | ALDH1A1 (0.58) | SYKHTR2BTSHRCYP2D6HTR2A | |
| SCHEMBL12781713 | 0.81 | SYK (0.56) | SYKPOLBHTR2CHTR2BPDPK1 | |
| SCHEMBL12312257 | 0.81 | ALDH1A1 (0.58) | SYKHTR2CHTR2BKITTSHR | |
| SCHEMBL2088116 | 0.80 | SYK (0.65) | SYKPOLBHTR2CHTR2BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | SYK 2801/4885POLB 52/4885HTR2C 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.